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by the French PAH Network between 1 January, 2003, and 1 April, 2010. For all cases, PAH was defined as a mPAP >= 25 mmHg associated with normal PCWP. Cases with known pathogenic mutations in BMPR2 or ACVRL1 were excluded. Further details have been published 7 . The control group was composed of a random sample of 1,140 subjects who were free of any chronic disease from the 3C Study 8 . The 3C Study is a population-based prospective cohort with a 4-year follow-up carried out in three French cities: Bordeaux (southwest France), Montpellier (southeast France) and Dijon (central eastern France). 9 , Germany. Individuals in the Focus cohort with BMI>30 were excluded. All IPAH cases and UK controls were genotyped at King's College London on an Illumina HiScan system, whilst genotype data for the German controls were generated by Popgen 10 .
British Heart Foundation Pulmonary Arterial Hypertension GWAS (BHFPAH) study
All patients in all cohorts studied were consented using either NIHRBR study consent forms (UK Research Ethics Committee: 13/EE/0325), PAHB consent forms (R24HL105333), BHFPAH consent forms (08/H0802/32) or local tissue bank consent forms allowing genetic testing. The use of DNA from the PAHB controls for genetics studies has been approved by the Institutional Review Board at VU as described previously) 3, 5 .
Vasoresponders are defined as patients who showed a significant drop in pulmonary artery pressure in response to acute vasodilator exposure at cardiac catheterisation. These patients subsequently go on to show good clinical outcomes on calcium channel blocker vasodilator therapy 11 .
The data collected within each study were collected according to standard SOPs determined at the initiation of each study and monitored by a central site for each study.
Whole-genome DNA sequencing in NIHRBR study
DNA extracted from venous blood underwent whole-genome sequencing using the Illumina TruSeq DNA PCR-Free Sample Preparation kit (Illumina Inc., San Diego, CA, USA) and Illumina HiSeq 2500 or HiSeq X sequencer, generating 100 -150 bp reads with a minimum coverage of 15X for ~95% of the genome (mean coverage of 35X). Throughout the project the read length chemistries used were 100 bp (n=357), then 125 bp (n=3074), and finally 150bp (n=5586). Sequencing reads were pre-processed by Illumina with Isaac Aligner and Variant Caller (v2, Illumina Inc.) using human genome assembly GRCh37 as reference. Variants were normalised and merged into a multi-sample VCF file using the gvcf aggregation tool 'agg'. Samples with potential handling errors (n=3) were excluded.
Genotyping of PAHB patient cohort and controls
DNA extracted from venous blood of both cases and controls was genotyped using Illumina HumanOmni5 Bead Chip system (Illumina, San Diego, CA). Genomic DNA prepared at the PAH 1 ). Related individuals were grouped into family networks and the (i) most inter-connected and/or (ii) first-sequenced individuals in each family were removed sequentially until no further related individuals remained (n=1,209 excluded).
To define remaining population structure principal components were calculated in the European individuals included in the analysis using the same 35,114 variants described above.
In the UK discovery analysis, the final group consisted of 5895 individuals including 847 PAH patients, recruits to Genomics England Ltd (GEL, n=1,102, 21.8% of non-PAH), individuals with bleeding, thrombotic and platelet disorders (BPD, n=834, 16.5%), primary immune disorders (PID, n=802, 15.9%), retinal dystrophies/paediatric neurology and metabolic disease (SPEED, n=774, 15.3%), multiple primary tumours (MPMT, n=472, 9.4%), hypertrophic cardiomyopathy (HCM, n=202, 4.0%), intrahepatic cholestasis of pregnancy (ICP, n=184, 3.7%), steroid resistant nephrotic syndrome (SRNS, n=154, 3.1%), primary membranoproliferative glomerulonephritis (PMG, n=133, 2.6%), cerebral small vessel disease (CSVD, n=126, 2.5%), neuropathic pain disorder (NPD, n=117, 2.3%), stem cell and myeloid disorder (SMD, n=79, 1.6%), leber hereditary optic neuropathy (LHON, n=53, 1.1%), Ehlers-Danlos syndrome (EDS, n=11, 0.2%) and others (CNTRL, n=5, 0.1%), or their first degree relatives.
Sample QC in PAHB study
For PAH Biobank cases, raw data, call rates, and quality scores were visualized (Illumina GenomeStudio). Patient samples with low genotyping rate (<95%) and gender discordance between clinical data and genomic data (n=8) were excluded for final genotyping calling. SNPs with call frequency < 97%, cluster separation <0.45, AA R, AB R, and BB R mean ≤0.2, 10% GenCall score ≤0.3, Het Excess >0.2, A//B frequency >0.5, and AB T mean <0.15 or >0.85 were removed. For the controls, genotype calling was performed at Vanderbilt University (VU). A total of 2,101 PAH cases were successfully genotyped. Control genotype data were cleaned using the quality control pipeline developed by the eMERGE Genomics Working Group 6 .
For each dataset, we excluded samples with (i) high degree of relatedness and (ii) race/ethnicity discordance between recorded clinical data and genomic data. Identity-By-Descent (IBD-pairwise) analysis was performed to identify potentially related or duplicated samples. After removing individuals self-identified as other than non-Hispanic European ancestry, case and control individuals' genomic ancestry was assessed using data from 1000 Genomes Project including individual of European, East and South Asian, and African ancestry through the use of principal component analysis. A total of 200,448 independent, common SNPs were included in the principal component analysis. Individuals who did not cluster with 1000 Genome Project European Populations were removed.
Imputation in PAHB study
The 1,740,956 successfully genotyped SNPs were included for imputation. Imputation was performed using Michigan Imputation Server 12 . After removing duplicated SNPs and SNPs with ambiguous alleles, and correcting strand, VCF files were uploaded to their server. The phasing of genotype data were done using Eagle version 2.3 13 . Imputation was performed using the Minimac3 algorithm and the Haplotype Reference Consortium panel 14 . After the imputation, there were a total of 39,148,816
SNPs. We excluded 31,421,226 SNPs due to insufficient quality control metrics and low frequency, including poor imputation quality (Rsq<0.3), MAF≤1%, and Hardy Weinberg Equilibrium P-value <0.00001. A total of 7,727,590 SNPs were included for statistical analysis.
QC in BHFPAH study
To ensure the replication cohort was independent from the samples used for GWAS discovery, the complete BHFPAH and NIHR-BR datasets were compared using identity-by-descent analysis in plink and related samples were removed from the BHFPAH cohort. Standard GWAS QC was performed on this subsample. Variant QC included selection of autosomes only, exclusion of duplicate and ambiguous variants, alignment to the forward strand (merged with 1000 Genomes), exclusion of variants with excess missingness (>0.05), exclusion of variants with significant differences in call rate between cases and controls, exclusion of rare variants (MAF<0.01), and exclusion of variants with significant HWE deviation (p<1x10-05 in controls). Sample QC included exclusion of heterozygosity outliers (>3SD), duplicated/ related individuals (IBD>0.1875), reported and genotyped sex mismatches, and population PCA outliers. The final cohort used for analysis comprised 275 cases (n=136 German, n=139 UK) and 1,983 controls (n=509 German FOCUS sample, n=1474 UK). Post QC, genotypes were imputed to 1000 Genomes phase 3 version 5 using the Michigan Imputation Server. Post imputation, SNPs were filtered on minor allele frequency (MAF>=0.01) and estimated imputation accuracy (INFO/R2>=0.7). Logistic regression association analyses were run in PLINK with the first 10 principal components of the genotype data.
Sensitivity analyses
Sensitivity analyses excluding 1) cases with rare clearly pathogenic or likely pathogenic BMPR2 variants or 2) each of the disease control groups in the NIHRBR (rare diseases) and PAHB data were performed to evaluate the influence by these subgroups on the stability of observed effects.
Credible set analysis
We applied credible set fine-mapping 15 to dissect the potential causal variants driving the observed associations. The P-values from the meta-analysis results including all four studies were converted into Bayes' Factors (BF) following the notation of Fuchsberger et al. 16 , and posterior probabilities for each BF were calculated by dividing each value by the sum of all BFs within +/-200 kb region of the lead SNP. We further ranked the posterior probabilities from the largest to the smallest, and formed 99% credible sets by summing up the ranked posterior probabilities until the cumulative sum reached 0.99.
Effects of novel loci on clinical phenotypes
Associations between novel loci and clinical phenotypes, including age, sex, haemodynamics, PAH functional class and co-morbidities in PAH cases were tested using Kruskal Wallis ANOVA for continuous variables and Cochran-Armitage test (assuming an additive model) for categorical variables, or the linear-by-linear test for functional class. P-values corrected for false discovery rate (FDR)<0.05 were considered significant.
Assessment of the SOX17 locus
Hi-C data from the Hi-C browser 17 Figure  S9B ) and used for subsequent experiments. The sequence of the guide RNAs is provided in Table  S12 .
Lentiviral particles were prepared by co-transfection of the CRISPRi lentiviral plasmids with lentiviral packaging plasmids pMDLg/pRRE (Addgene #12251), pRSV-Rev (Addgene #12253) and pMD2.G (Addgene #12259) packaging/envelope into 70% confluent human 293FT cells (Invitrogen) using PEIpro DNA transfection reagent (Polyplus Transfection, Illkirch France). Lentiviral supernatant was harvested 72 h after transfection, and concentrated with Lenti-X Concentrator (Clontech, Mountain View US) following manufacturer's instructions. Human pulmonary arterial endothelial cells were transduced with 10μl of concentrated lentivirus for 48h followed by a selection with 10μg/mL blasticidin (Gibco/Thermofisher Scientific, Hempstead UK) for 72h.
SOX17 expression
After 72h of blasticidin selection, cells were lysed and mRNA was extracted using Qiagen RNeasy kit (Qiagen, Manchester UK). Reverse transcriptase polymerase chain reaction (RT-PCR) was performed using Multiscribe Reverse Transciptase (Applied Biosystems/ThermoFisher Scientific), followed by quantitative PCR, using PowerSYBRgreen mastermix (Applied Biosystems/ThermoFisher Scientific).
Relative expression of the gene of interest (GOI) was calculated as 2^(CT value [GOI] -CT value
[ACTB1]), in which ACTB1 served as housekeeping gene. In addition to SOX17, the relative expression of two neighbouring genes (MRPL15 and TMEM68) was measured. The primer sequences used for qPCR were designed using PrimerBlast, and are provided in Table S12 .
Haplotype-specific Luciferase assay
Genomic DNA (gDNA) was isolated from blood-outgrowth endothelial cells (BOECs) using a QiaAmp DNA Mini kit (Qiagen). BOECs were isolated and cultured as previously described 22 ; for haplotype-specific reporter assays gDNA was isolated from a patient heterozygous for rs13266183. Primers were designed (http://nebuilder.neb.com/) to clone 100bp gDNA areas containing each of the SNPs in the credible set which overlapped the epigenomic data indicating likely enhancer function ( Figure 2B ). Primers were flanked by sequences compatible with KpnI restriction sites (Table S12) . Inserts were obtained by Q5-based polymerase chain reactions (New England Biolabs, Ipswich, Massachusetts), and purified after gel electrophoresis. The purified product was cloned into the multiple cloning site of pGL4.23 firefly luciferase vector (Promega, Madison, Wisonsin), followed by transformation of the final vector and insert into stable Top10 E.coli. Plasmid DNA was extracted from multiple bacterial colonies, and sent for Sanger sequencing to obtain plasmids with haplotypespecific inserts, i.e. A versus G at rs10958403. Human pulmonary artery endothelial cells (HPAECs) were transfected with either of these plasmids, using AMAXA electroporation (device: Nucleofector I, programme: M-03, kit: VPI-1001, Lonza, Basel, Switzerland). The empty pGL4.23 vector served as control, while a Renilla luciferase plasmid (Promega) was co-transfected to control for transfection efficiency. 24h after transfection cells were lysed, followed by measurement of firefly luciferase and Renilla luciferase (Dual Luciferase Reporter Assay, Promega). Data are presented as fold-induction of the luciferase/Renilla ratio compared to the empty vector.
Software
Bcftools (v1.2) 23 , vcftools (v0.1.14) 24 , plink (v1.90beta) 25 , R 26 and RStudio 27 with associated packages 
Supplementary Results

Definition of key variants and sensitivity analyses
Sets of variants most likely to be causal ('credible sets') at the two novel PAH loci comprised 9 variants at HLA-DPA1/DPB1 and 4 and 31 at the two SOX17 signals, respectively (Table S3 ).
The strength of association with the HLA-DPA1/DPB1 and SOX17 signals was not altered after exclusion of 161 (NIHRBR) and 54 (PAHB) cases with pathogenic 28 rare heterozygous variants in BMPR2 (Table S4) . Similar results were seen after removing patients with any monogenic cause of PAH, including BMPR2 mutations (Table S4 ). In additional sensitivity analyses, removing other rare diseases from non-PAH controls did not change the strength of association with the top signals (Table  S4) .
Association between PAH and known expression quantitative trait loci (eQTL)
We queried the Genotype-Tissue Expression (GTEx) database (https://www.gtexportal.org, accessed 27/09/2017) to examine the potential downstream regulatory effects of the SNPs associated with PAH in different tissues but found none were associated with Sox17 expression, and the Sox17 eQTLs present in both GTEx and the discovery GWAS analyses (rs2375863, rs1123133, rs79519760 and rs142492583) were not associated with PAH (p>0.5 in all). For HLA-DPB1 all eQTLs present in the GWAS analysis were in LD with rs1811359, which was also not associated with PAH (p=0.9).
Association between HLA-DPB1 locus and outcomes in incident PAH
Survival analyses were repeated after removal of (i) cases with rare, pathogenic BMPR2 mutations and (ii) any rare, pathogenic mutation in known PAH genes, with similar results ( Figure S4) . A subanalysis within 192 NIHRBR/PAHB incident cases (enrolled within 6 months of diagnosis) showed, for rs2856830, a minor allele frequency, MAF=0.16 (versus MAF=0.12 in controls and MAF=0.20 in all cases) and a similar separation in survival curves by genotype ( Figure S4E ).
Analysis of 673 PAH patients diagnosed since 2010 with follow-up, who would have had access to all modern medications under the same treatment guidelines, showed a similar difference in survival by copies of the C allele of rs2856830, with estimated 5-year survival of 100% in C/C homozygotes [data not shown].
PAH locus at HLA-DPA1/DPB1
The lead variant rs2856830 is in weak LD with variants associated with vasculitis and systemic sclerosis, conditions which are themselves associated with PAH (rs9277341 29 Figure S5 ). The residues that differ between the most common HLA-DPB1*0201 (enriched) and DPB1*0401 (depleted) alleles are at positions 36, 55, 56 and 69 (Table 2 and Table S9 ). These residues were also associated with rs2856830 genotype, diagnosis of PAH (versus controls) and survival in PAH patients (Table S9) . Table S1 -Genotyping details and quality controls of studies. *patients with rare mutations in PAH genes were specifically excluded from recruitment to this study. Table S9 -HLA types associated with PAH in Europeans after FDR-correction.
Supplementary tables
Table S10 -Associations of HLA-DPB1 alleles and specific amino acid residues with the lead HLA-DPB1 SNP rs2856830, diagnosis of PAH and survival in PAH.
Orange indicates alleles and residues depleted in PAH cases and green indicates those enriched in PAH cases. Green to red shading of percentages and hazard ratios is used to indicate directionality of associations (green indicates enriched in genotype/associated with improved outcomes in PAH). 
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Table legends
Table S1 -Genotyping details and quality controls of studies Table S2 -Heterogeneity and imputation quality of lead SNPs across studies. I 2 -Heterogeneity index I2. Table S3 -Results for CBLN2 SNP from the published Paris GWAS, rs2217560, in GWAS analyses from this study. Table S4 -Credible sets of variants with 99% of the posterior probability. Variants from each signal were analysed and assigned a likelihood of being the causal variant. Table S10 -Associations of HLA-DPB1 alleles and specific amino acid residues with the lead HLA-DPB1 SNP rs2856830, diagnosis of PAH and survival in PAH. Orange indicates alleles and residues depleted in PAH cases and green indicates those enriched in PAH cases. Green to red shading of percentages and hazard ratios is used to indicate directionality of associations (green indicates enriched in genotype/associated with improved outcomes in PAH). Table S11 
